New Reference: Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma

Phase II, open-label, multicenter, multicohort study

The patient had to have experienced relapse or be ineligible for ASCT

Pembrolizumab (n=53)

cORR: 41.5% [22 of 53 pts]

CR: 20.8% [ 11of 53 pts]

mDoR: NR [NR-NR]

median PFS: 4.3 mos

Grade≥3: Neutropenia (13.2%), astenia (1.9%), AST increased (1.9%)

Zinzani Pier Luigi et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Reviewed by Elvin CHALABİYEV, MD on SEP 10, 2023